Melanoma      

Melanoma       image

Home » FOI request log » Melanoma      

FOI REFERENCE: 24163   FOI DATE: 12th June 2024    

Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage)?

  • Cobimetinib – 0 Patients
  • Dabrafenib – 0 Patients
  • Dabrafenib + Trametinib – *
  • Dacarbazine – 0 Patients
  • Denosumab- 0 Patients
  • Encorafenib + Binimetinib – 0 Patients
  • Ipilimumab monotherapy- 0 Patients
  • Ipilimumab + Nivolumab – 0 Patients
  • Nivolumab monotherapy- 0 Patients
  • Nivolumab + Relatlimab- 0 Patients
  • Pembrolizumab  – *
  • Trametinib- 0 Patients
  • Vemurafenib- 0 Patients
  • Vemurafenib + Cobimetinib- 0 Patients
  • Other active systemic anti-cancer therapy-Acalabrutinin-1 Carboplatin Auc – *
  • Palliative care only- *

Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

  • Ipilimumab monotherapy – 0 Patients
  • Ipilimumab + Nivolumab – 0 Patients
  • Nivolumab monotherapy – 0 Patients
  • Nivolumab + Relatlimab – 0 Patients
  • Pembrolizumab   – 0 Patients
  • Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib  /Trametinib  /Vemurafenib  /Vemurafenib AND Cobimetinib)  – 0 Patients
  • Other active systemic anti-cancer therapy – 0 Patients
  • Palliative care only – 0 Patients

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

  • Ipilimumab (monotherapy) 0 Patients
  • Nivolumab (monotherapy) 0 Patients
  • Nivolumab AND Ipilimumab (combination) 0 Patients
  • Nivolumab AND Relatlimab 0 Patients
  • Pembrolizumab 0 Patients
  • Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) 0 Patients
  • Other active systemic anti-cancer therapy 0 Patients

Print this page
Email this page